{"groups":[{"description":"INDUCTION (28-day cycles for 8 cycles):\n\n* VELCADE 1.3 mg/m2 subcutaneously (SC) days 1, 8 and 15\n* Cyclophosphamide 300 mg/m2 orally (PO) days 1, 8 and 15\n* Dexamethasone 40 mg PO days 1,8 and 15\n\nMAINTENANCE (28-day alternating cycles until stopped for toxicity, relapse or death):\n\n* Odd cycles (9, 11, 13, etc.) lenalidomide 10 mg PO days 1-21\n* Even cycles (10, 12, 14, etc.) VELCADE 1.3 mg/m2 SC days 1, 15\n\nVelcade: Bortezomib induction: 1.3 mg/m2, given subcutaneously (SC) on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Bortezomib maintenance (even cycles \\[10,12,14, etc.\\]: 1.3 mg/m2, given SC on days 1 and 15. For patients who required VELCADE dose reductions during induction, the last administered mg/m2 dose of VELCADE will be the starting dose for maintenance, given on days 1 and 15. Maintenance cycles will last 28 days and continue indefinitely, until","id":"FG000","title":"Velcade, Cyclophosphamide, Revlimid"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"16"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"14"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"17 subjects consented to the study. 1 subject was a screen failure."}